Novo Nordisk aims for three new Dicerna drug candidates a year

Novo Nordisk’s ambition with the acquisition of Dicerna is to start three clinical studies a year, says Chief Scientific Officer Marcus Schindler at the company’s capital markets day.
by marketwire, translated by daniel pedersen

In fall of last year, Danish pharmaceutical firm Novo Nordisk acquired US-based Dicerna for USD 3.3bn. The purchase will bring in several drug candidates annually, says Marcus Schindler, chief scientific officer at Novo Nordisk, at the company’s capital markets day on Thursday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading